On June 19, "Shine the LIght on Sickle Cell" in celebration of World Sickle Cell Day!

Our Inspiration

William E. Proudford was a devoted family man, colleague, and friend who led by example, shared his joy, but never his sorrows; did not raise his voice above a whisper, and yet spoke with conviction. His calm nature and strong character brought out the best in every person he encountered.

He had a love for learning all of his life and set an example of consistently searching for opportunities to enhance his personal development. While in the Air Force, he obtained his GED, became fluent in German and even took a course in Russian. After completing 24 years of service in the Air Force, he excelled at Delaware State College, graduating summa cum laude and earning membership in the top honor societies. An avid reader and fast learner, he went on to earn a Master’s degree and to learn new skills throughout his life.

Despite a number of physical challenges, including sickle cell disease, progressive and profound hearing loss, diabetes and kidney failure, he always maintained the quiet, unassuming and steady manner that made him the bedrock of his family.

Our Vision

A World Without Sickle Cell Disease

Our Mission

To support sickle cell awareness, education, state-of-the-art treatment and research, and to bring hope to families affected by this devastating disease.

History

On August 31, 2004, William E. Proudford passed away of complications of kidney disease resulting from diabetes. Mr. Proudford also suffered from sickle cell disease (SCD), Paget’s disease and profound hearing loss. Because of the unique challenges they encountered in understanding and getting adequate treatment for his sickle cell disease, his family started an effort to raise awareness about the disease. In October, 2005, the William E. Proudford Sickle Cell Fund, Inc. (WEPSCF) was incorporated in Delaware as a non-profit organization. The organization received its 501(c)(3) tax-exempt status in March, 2006. The Proudford family donated $5,000 to start the Fund, and immediately began building partnerships with area organizations such as Mjach Designs, Baltimore, who developed the organization’s logo, Dreamhaus Media LLC, Dallas, who designed the organization’s original website, and Richards, Layton & Finger, P.A., who provided legal assistance.

Board of Directors

Karen L. Proudford, Ph.D. is an academic whose teaching, research, writing and consulting interests include group and intergroup dynamics, leadership, diversity and conflict. She received her B.S. degree in Accounting summa cum laude from Florida A&M University and her M.A. and Ph.D. degrees in Management from the Wharton School of the University of Pennsylvania. Prior to beginning her career in academia, she held positions at Honeywell, Inc. and IBM. She was named by The Maryland Daily Record as one of the Top 100 Women in Maryland in 2009 and 2013; she was inducted into the Top 100 Women Circle of Excellence in 2015. In 2010, she was selected for inclusion in the inaugural edition of Who’s Who in Black Baltimore. In 2011, Dr. Proudford was awarded a Fulbright Senior Specialist Award to visit the prestigious Richard Ivey School of Business at the University of Western Ontario, Canada. In addition, she was inducted into the School of Business and Industry Hall of Fame at her alma mater, Florida A&M University. Dr. Proudford is a past Chair of the Board of Directors of the American Red Cross — Greater Chesapeake and Potomac Region Blood Services Division.  She currently serves on the Maryland Life Sciences Advisory Board and the Reginald F. Lewis Museum Board.

Marc V. Proudford has career service in both the public and private sectors. Prior career service includes positions with the University of Maryland Medical System, AAI Corporation, and, Paine Webber/UBS. He has a B.S. degree in Business Administration from the University of Delaware, Master of Business Administration and Master of Science in Human Resources degrees from Wilmington College, designation as a Senior Professional in Human Resources designation from the Society of Human Resources, Certified Compensation Professional from WorldatWork, and Health Insurance Associate and Managed Care Professional certifications from the Health Insurance Associate of America. He has served as a mediator and facilitator with the State of Maryland Shared Neutrals Program, Maryland Commission for Civil Rights, District Court of Baltimore City and the Equal Employment Opportunity Commission.

William E. Proudford II has over 25 years experience in administration, sales, banking and public relations. He is currently employed by Delaware Express and has worked for the Bank of New York, Traveler’s Bank and Citigroup. Mr. Proudford is an Air Force veteran and served for four years as an administrative specialist stationed around the United States and in Okinawa.

Rubye T. Proudford, R.N., received her B.S. degree, with a major in Nursing and a minor in Science, from Florida Agricultural and Mechanical University. After serving as a commissioned U.S. Air Force nurse, she continued her professional career as a civilian nurse in military hospitals throughout the United States and in Germany. She also was an Instructor in Theory and Clinical Obstetrics and Gynecology (OB) at Delaware Technical and Community College, Georgetown, Delaware. Mrs. Proudford’s professional memberships included the Nurses Association of American College of Obstetricians and Gynecologists (NAACOG), the National League of Nursing (NLN) and fraternal membership in Delta Sigma Theta Sorority, Inc., Dover Alumnae Chapter.

John Mark Zeberkiewicz is a director in the corporate advisory group of Richards, Layton & Finger, P.A., the largest law firm in Delaware. His practice focuses on transactional matters involving Delaware corporations, including mergers and acquisitions, corporate governance and corporate finance, and he has published several articles on matters of corporate law. He also has particular expertise in Delaware law regarding nonstock corporations, having served on the drafting subcommittee responsible for the 2010 nonstock amendments to Delaware’s General Corporation Law. Mr. Zeberkiewicz received his J.D., cum laude, from the University of Pennsylvania Law School, where he served as Articles Editor of the University of Pennsylvania Journal of International Economic Law, and his B.A., magna cum laude, from the University of Delaware, where he was elected to Phi Beta Kappa.

Dr. Joseph is a Medical Director at CareFirst BlueCross BlueShield. He graduated from the College of the Holy Cross, Worcester, MA. with a BA degree in Biology Pre-Medicine and accepted a U.S. Air Force Reserve Officers’ Training Corps Commission as a Second Lieutenant. He earned his Doctor of Medicine from Boston University. Dr. Joseph completed a Flexible Internship at Malcolm Grow USAF Medical Center, Andrews Air Force Base, MD.. He trained in Aerospace Medicine at Brooks, AFB, San Antonio, Texas and was assigned as a Flight Surgeon to Andrews AFB, MD. He traveled worldwide supporting White House and Congressional Special Air Missions. Dr. Joseph completed an Occupational Medicine Residency and a Master’s Degree in Public Health at Johns Hopkins University, Baltimore, Maryland. He also completed military assignments at Robins AFB, Georgia; Elmendorf AFB, Alaska and the Pentagon. Dr. Joseph retired from active duty after 20 years with an Aeronautical Rating of Chief Flight Surgeon the rank of Colonel. In 1998, after his military retirement Dr. Joseph joined CareFirst and has served on the Adventist HealthCare Centers’ Health Disparities Inaugural Advisory Board; Maryland Steering Committee for Adults with Sickle Cell Disease; as Vice Chair of the Leadership and Capacity Building and as Vice Chair for the Cultural and Linguistic Competency Workgroups of the Maryland Health Disparities Collaborative. He serves on the board of directors for Community Health Partnership, Inc., Washington D.C. Dr. Joseph is licensed to practice medicine in the State of Maryland.

INDIVIDUALS LIVING WITH SCD IN THE U.S.

HOSPITALIZATIONS ANNUALLY DUE TO SCD IN THE U.S.

NEW DRUG APPROVED BY FDA IN LAST 20 YEARS

NEW DRUGS CURRENTLY IN PHASE III CLINICAL TRIALS